LT2961771T - Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams - Google Patents
Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenamsInfo
- Publication number
- LT2961771T LT2961771T LTEP14708507.0T LT14708507T LT2961771T LT 2961771 T LT2961771 T LT 2961771T LT 14708507 T LT14708507 T LT 14708507T LT 2961771 T LT2961771 T LT 2961771T
- Authority
- LT
- Lithuania
- Prior art keywords
- cea
- bispecific
- antigen binding
- binding molecules
- cell activating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13156686 | 2013-02-26 | ||
PCT/EP2014/053490 WO2014131712A1 (en) | 2013-02-26 | 2014-02-24 | Bispecific t cell activating antigen binding molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
LT2961771T true LT2961771T (lt) | 2020-03-10 |
Family
ID=47748528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP14708507.0T LT2961771T (lt) | 2013-02-26 | 2014-02-24 | Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams |
Country Status (33)
Country | Link |
---|---|
US (11) | US10155815B2 (lt) |
EP (2) | EP3708584A1 (lt) |
JP (4) | JP6133444B2 (lt) |
KR (5) | KR101833602B1 (lt) |
CN (2) | CN110437337A (lt) |
AR (1) | AR094896A1 (lt) |
AU (3) | AU2014222779B2 (lt) |
BR (1) | BR112015015824B1 (lt) |
CA (1) | CA2891493C (lt) |
CL (1) | CL2015001988A1 (lt) |
CR (1) | CR20150393A (lt) |
DK (1) | DK2961771T3 (lt) |
EA (2) | EA201891502A1 (lt) |
ES (1) | ES2775207T3 (lt) |
HK (1) | HK1211300A1 (lt) |
HR (1) | HRP20200306T1 (lt) |
HU (1) | HUE047925T2 (lt) |
IL (2) | IL240045B (lt) |
LT (1) | LT2961771T (lt) |
MA (1) | MA38308B1 (lt) |
MX (2) | MX2015008920A (lt) |
MY (1) | MY192312A (lt) |
NZ (1) | NZ708182A (lt) |
PE (1) | PE20151410A1 (lt) |
PH (1) | PH12015501340B1 (lt) |
PL (1) | PL2961771T3 (lt) |
PT (1) | PT2961771T (lt) |
RS (1) | RS59992B1 (lt) |
SG (1) | SG11201504497TA (lt) |
SI (1) | SI2961771T1 (lt) |
TW (2) | TWI638832B (lt) |
UA (1) | UA119320C2 (lt) |
WO (1) | WO2014131712A1 (lt) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2657856T3 (es) * | 2011-03-02 | 2018-03-07 | Roche Glycart Ag | Anticuerpos CEA |
JP6159724B2 (ja) | 2011-08-23 | 2017-07-05 | ロシュ グリクアート アーゲー | T細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法 |
JP6152120B2 (ja) | 2012-02-15 | 2017-06-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Fc受容体に基づくアフィニティークロマトグラフィー |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
BR112015007120A2 (pt) | 2012-10-08 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo |
EA201891502A1 (ru) | 2013-02-26 | 2018-12-28 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
MX2015010350A (es) | 2013-02-26 | 2015-10-29 | Roche Glycart Ag | Moleculas de union a antigeno biespecificas que activan la celula t. |
WO2015080981A1 (en) | 2013-11-27 | 2015-06-04 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
KR102317315B1 (ko) | 2014-08-04 | 2021-10-27 | 에프. 호프만-라 로슈 아게 | 이중특이적 t 세포 활성화 항원 결합 분자 |
US11952421B2 (en) | 2014-10-09 | 2024-04-09 | Bristol-Myers Squibb Company | Bispecific antibodies against CD3EPSILON and ROR1 |
EP3204416A1 (en) * | 2014-10-09 | 2017-08-16 | EngMab AG | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer |
JP6707090B2 (ja) | 2014-11-06 | 2020-06-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | FcRn結合が変更されたFc領域変種および使用方法 |
JP6779873B2 (ja) * | 2014-11-12 | 2020-11-04 | メモリアル スローン ケタリング キャンサー センター | 抗コンドロイチン硫酸プロテオグリカン4抗体およびその使用 |
RS61870B1 (sr) * | 2014-11-14 | 2021-06-30 | Hoffmann La Roche | Antigen vezujući molekuli koji sadrže trimer liganda iz tnf familije |
MX2017006626A (es) * | 2014-11-20 | 2017-08-21 | Hoffmann La Roche | Cadenas ligeras comunes y metodos de uso. |
ES2835823T3 (es) * | 2014-11-20 | 2021-06-23 | Hoffmann La Roche | Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1 |
CR20170230A (es) | 2014-12-05 | 2017-11-07 | Genentech Inc | Anticuerpos anti-cd79b y métodos de uso |
US20170369588A1 (en) * | 2014-12-23 | 2017-12-28 | Universita' Degli Studi Di Parma | Pro-apoptotic anti-ng2/cspg4 antibodies and their uses for disease therapy |
CN114652827A (zh) | 2015-05-29 | 2022-06-24 | 安普希韦纳治疗公司 | 双特异性cd33和cd3结合蛋白质的使用方法 |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Egfrviii及cd3抗體構築體 |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
US20170096495A1 (en) * | 2015-10-02 | 2017-04-06 | Hoffmann-La Roche Inc. | Bispecific t cell activating antigen binding molecules |
MA43018B1 (fr) | 2015-10-02 | 2021-11-30 | Hoffmann La Roche | Anticorps anti-pd1 et procédés d'utilisation |
KR20180073561A (ko) * | 2015-10-02 | 2018-07-02 | 에프. 호프만-라 로슈 아게 | 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자 |
AR106365A1 (es) * | 2015-10-02 | 2018-01-10 | Hoffmann La Roche | Moléculas biespecíficas de unión a antígeno activadoras de células t |
RS62437B1 (sr) | 2015-10-25 | 2021-11-30 | Sanofi Sa | Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
CN108290954B (zh) | 2015-12-09 | 2022-07-26 | 豪夫迈·罗氏有限公司 | Ii型抗cd20抗体用于降低抗药物抗体形成 |
CN108368179B (zh) | 2016-01-08 | 2022-08-23 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法 |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
SI3433280T1 (sl) | 2016-03-22 | 2023-07-31 | F. Hoffmann-La Roche Ag | S proteazo aktivirane bispecifične molekule celic T |
EP4257193A3 (en) | 2016-04-13 | 2024-01-24 | Sanofi | Trispecific and/or trivalent binding proteins |
JP7195929B2 (ja) | 2016-04-13 | 2022-12-26 | サノフイ | 三重特異性および/または三価結合タンパク質 |
AU2017291262A1 (en) | 2016-06-30 | 2019-01-03 | F. Hoffmann-La Roche Ag | Improved adoptive T-cell therapy |
TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途 |
JP7022123B2 (ja) | 2016-09-30 | 2022-02-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Cd3に対する二重特異性抗体 |
IL267284B2 (en) * | 2016-12-19 | 2023-03-01 | Hoffmann La Roche | Combination therapy with a targeted 4-bb1 agonist (cd137) |
CA3221995A1 (en) | 2017-02-08 | 2018-08-16 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
EP3585424A4 (en) * | 2017-02-27 | 2021-01-13 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS TARGETED BY CAIX, ANO1, MESOTHELIN, TROP2, CEA OR CLAUDIN-18.2 |
WO2018162517A1 (en) | 2017-03-10 | 2018-09-13 | F. Hoffmann-La Roche Ag | Method for producing multispecific antibodies |
TWI747215B (zh) | 2017-04-05 | 2021-11-21 | 瑞士商赫孚孟拉羅股份公司 | 特異性結合至pd1至lag3的雙特異性抗體 |
EP3615074A4 (en) * | 2017-04-26 | 2020-05-13 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
EP3409322A1 (en) * | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
PE20200619A1 (es) * | 2017-06-07 | 2020-03-11 | Spark Therapeutics Inc | AGENTES POTENCIADORES PARA LA TRANSFECCION CELULAR MEJORADA Y/O LA PRODUCCION DEL VECTOR rAAV |
WO2019012138A1 (en) * | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | POLYPEPTIDE MOLECULE WITH IMPROVED DOUBLE-SPECIFICITY |
EP3658183A1 (en) * | 2017-07-28 | 2020-06-03 | H. Hoffnabb-La Roche Ag | Bispecific antibody formulation |
CA3076867A1 (en) * | 2017-10-03 | 2019-04-11 | Merck Patent Gmbh | Cysteine engineered antigen-binding molecules |
KR20200084006A (ko) * | 2017-11-01 | 2020-07-09 | 에프. 호프만-라 로슈 아게 | 표적화된 ox40 작용제를 사용하는 병용 요법 |
AU2018382966A1 (en) * | 2017-12-14 | 2020-04-09 | F. Hoffmann-La Roche Ag | Use of a CEA CD3 bispecific antibody and a PD-1 axis binding antagonist in a dosage regime to treat cancer |
EP3502140A1 (en) | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
AR115360A1 (es) | 2018-02-08 | 2021-01-13 | Genentech Inc | Moléculas de unión al antígeno y métodos de uso |
TWI829667B (zh) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
EP3759491A1 (en) * | 2018-03-01 | 2021-01-06 | H. Hoffnabb-La Roche Ag | Specificity assay for novel target antigen binding moieties |
SG11202007961QA (en) * | 2018-04-13 | 2020-09-29 | Hoffmann La Roche | Her2-targeting antigen binding molecules comprising 4-1bbl |
US20210179734A1 (en) * | 2018-04-17 | 2021-06-17 | Invenra Inc. | Trivalent trispecific antibody constructs |
US11555071B2 (en) | 2018-06-03 | 2023-01-17 | Lamkap Bio Beta Ltd. | Bispecific antibodies against CEACAM5 and CD47 |
CR20210330A (es) * | 2018-12-21 | 2021-07-20 | Hoffmann La Roche | ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325) |
US11608376B2 (en) | 2018-12-21 | 2023-03-21 | Hoffmann-La Roche Inc. | Tumor-targeted agonistic CD28 antigen binding molecules |
WO2020169698A1 (en) * | 2019-02-21 | 2020-08-27 | F. Hoffmann-La Roche Ag | Sensitization of cancer cells to tnf by bet inhibition |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
WO2020208124A1 (en) | 2019-04-12 | 2020-10-15 | F. Hoffmann-La Roche Ag | Treatment of cancer using a cea cd3 bispecific antibody and a wnt signaling inhibitor |
CA3140287A1 (en) * | 2019-06-19 | 2020-12-24 | Johannes Auer | Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
CN114531878A (zh) | 2019-06-27 | 2022-05-24 | 豪夫迈·罗氏有限公司 | 新颖icos抗体及包含它们的肿瘤靶向抗原结合分子 |
AR119382A1 (es) | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
JP2022543551A (ja) | 2019-07-31 | 2022-10-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Gprc5dに結合する抗体 |
KR20220028035A (ko) | 2019-07-31 | 2022-03-08 | 에프. 호프만-라 로슈 아게 | Gprc5d에 결합하는 항체 |
BR112022004995A2 (pt) | 2019-09-18 | 2022-06-21 | Lamkap Bio Alpha AG | Anticorpos biespecíficos contra ceacam5 e cd3 |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
AU2021291011A1 (en) | 2020-06-19 | 2023-01-05 | F. Hoffmann-La Roche Ag | Antibodies binding to CD3 and CD19 |
WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
EP4168445A1 (en) | 2020-06-19 | 2023-04-26 | F. Hoffmann-La Roche AG | Immune activating fc domain binding molecules |
AU2021291005A1 (en) | 2020-06-19 | 2023-01-05 | F. Hoffmann-La Roche Ag | Antibodies binding to CD3 and FolR1 |
CN115698084A (zh) | 2020-06-19 | 2023-02-03 | 豪夫迈·罗氏有限公司 | 与cd3结合的抗体 |
IL296429A (en) | 2020-06-19 | 2022-11-01 | Hoffmann La Roche | Protease-activated t-cell bispecific antibodies |
AU2021303508A1 (en) | 2020-07-10 | 2023-02-02 | F. Hoffmann-La Roche Ag | Antibodies which bind to cancer cells and target radionuclides to said cells |
EP4216998A1 (en) | 2020-09-24 | 2023-08-02 | F. Hoffmann-La Roche AG | Prevention or mitigation of t-cell bispecific antibody-related adverse effects |
EP4237450A1 (en) | 2020-10-30 | 2023-09-06 | F. Hoffmann-La Roche AG | Treatment of cancer using a cea cd3 bispecific antibody and a tgfbeta signaling inhibitor |
WO2022101120A1 (en) | 2020-11-10 | 2022-05-19 | F. Hoffmann-La Roche Ag | Prevention or mitigation of t-cell engaging agent-related adverse effects |
JP7326584B2 (ja) | 2020-12-17 | 2023-08-15 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗hla-g抗体及びその使用 |
KR20230121772A (ko) | 2020-12-18 | 2023-08-21 | 람카프 바이오 베타 엘티디. | Ceacam5 및 cd47에 대한 이중특이적 항체 |
EP4277705A1 (en) | 2021-01-12 | 2023-11-22 | F. Hoffmann-La Roche AG | Split antibodies which bind to cancer cells and target radionuclides to said cells |
EP4277668A1 (en) | 2021-01-13 | 2023-11-22 | F. Hoffmann-La Roche AG | Combination therapy |
JP2024508949A (ja) | 2021-03-09 | 2024-02-28 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pd-1標的化il-2変異体イムノコンジュゲートとfap/4-1bb結合分子との併用療法 |
AR126009A1 (es) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam |
AR127887A1 (es) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y plap |
US20240002544A1 (en) | 2022-03-07 | 2024-01-04 | Novimmune Sa | Cd28 bispecific antibodies for targeted t cell activation |
US20230302044A1 (en) * | 2022-03-28 | 2023-09-28 | Steve Reilly | Composition to increase cellularlongevity |
WO2023242351A1 (en) | 2022-06-16 | 2023-12-21 | Lamkap Bio Beta Ag | Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3 |
Family Cites Families (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1156905B (it) | 1977-04-18 | 1987-02-04 | Hitachi Metals Ltd | Articolo di ornamento atto ad essere fissato mediante un magnete permanente |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
WO1991003493A1 (en) | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
US5798100A (en) * | 1994-07-06 | 1998-08-25 | Immunomedics, Inc. | Multi-stage cascade boosting vaccine |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
FR2757863B1 (fr) * | 1996-12-27 | 1999-03-26 | Inovat Sarl | Nouvelles substances a activite biologique, leur procede d'obtention et les compositions en renfermant |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
AU2719099A (en) | 1998-01-23 | 1999-08-09 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Multipurpose antibody derivatives |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
MXPA02003456A (es) | 1999-10-04 | 2002-10-23 | Medicago Inc | Metodo para regular la transcripcion de genes foraneos. |
JP2003531588A (ja) * | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
US6773883B2 (en) | 2000-07-31 | 2004-08-10 | The Brigham & Women's Hospital, Inc. | Prognostic classification of endometrial cancer |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
HUE031632T2 (en) | 2003-11-05 | 2017-07-28 | Roche Glycart Ag | Antigen binding molecules with enhanced Fc receptor binding affinity and effector function |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
US7273608B2 (en) | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | ヒト化抗TGF−β抗体 |
EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
AR051836A1 (es) * | 2004-11-30 | 2007-02-14 | Centocor Inc | Antagonistas de receptor 3 simil toll metodos y usos |
DK1871805T3 (da) | 2005-02-07 | 2019-12-02 | Roche Glycart Ag | Antigenbindende molekyler der binder egfr, vektorer der koder derfor, og anvendelser deraf |
EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
CA2606081C (en) | 2005-04-26 | 2013-09-17 | Markus M. Heiss | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
BRPI0611445A2 (pt) | 2005-05-09 | 2010-09-08 | Glycart Biotechnology Ag | molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
MY169746A (en) | 2005-08-19 | 2019-05-14 | Abbvie Inc | Dual variable domain immunoglobulin and uses thereof |
EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
CA2633486C (en) | 2005-12-16 | 2015-02-03 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
BRPI0620632A2 (pt) | 2005-12-21 | 2011-12-20 | Micromet Ag | composições farmacêuticas com resistência a cea solúvel, processo de produção das mesmas, usos de anticorpo bi-especìfico de cadeia simples, molécula de ácido nucléico, vetor e hospedeiro na preparação de composição farmacêuticas, e kits |
CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
NZ612319A (en) | 2006-06-12 | 2015-04-24 | Emergent Product Dev Seattle | Single-chain multivalent binding proteins with effector function |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
TWI592425B (zh) * | 2006-10-02 | 2017-07-21 | E R 施貴寶&聖斯有限責任公司 | 與cxcr4結合之人抗體及彼之用途 |
RS53942B1 (en) | 2006-10-27 | 2015-08-31 | Genentech Inc. | Antibodies and Immunoconjugates and Their Use |
CN109456410B (zh) | 2007-04-03 | 2022-01-28 | 安进研发(慕尼黑)股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
ES2695047T3 (es) | 2007-04-03 | 2018-12-28 | Amgen Research (Munich) Gmbh | Dominio de unión específico entre especies |
WO2008119566A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
JP5490714B2 (ja) | 2007-11-28 | 2014-05-14 | メディミューン,エルエルシー | タンパク質製剤 |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) * | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
KR20110047255A (ko) | 2008-09-26 | 2011-05-06 | 로슈 글리카트 아게 | 이중특이적 항-egfr/항-igf-1r 항체 |
BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
EP2417156B1 (en) | 2009-04-07 | 2015-02-11 | Roche Glycart AG | Trivalent, bispecific antibodies |
EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
CA2761233A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
EP2261258A1 (de) | 2009-06-08 | 2010-12-15 | Schuler, Gerold | MCSP-gerichtete scFv-Antikörperfragmente und deren Verwendung |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
BR112012003983A2 (pt) | 2009-08-31 | 2021-09-14 | Roche Glycart Ag | Molecula de ligação abm moleculas de ligação de antigenos abm variante polipeptideo isolado molecula de ligação de antigeneos humanizada anticorpo polinucleotideo isolado composição vetor celula hospedeira metodo de produção de abm metodo de indução da lise celular de tumor, metodo de diagnostico de doença em pacientes que possuem um cancer metodo de aumento de tempo de sobrevivencia em pacientes que possuem um cancer metodo de indução em pacientes de regressão de um motor uso abm e invenção |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
EP2519544A1 (en) | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Polypeptide heterodimers and uses thereof |
AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
MX349057B (es) | 2010-11-30 | 2017-07-07 | Chugai Pharmaceutical Co Ltd | Agente terapeutico que induce citotoxicidad. |
JP5878182B2 (ja) | 2011-02-10 | 2016-03-08 | ロシュ グリクアート アーゲー | ミュータントインターロイキン−2ポリペプチド |
ES2657856T3 (es) | 2011-03-02 | 2018-03-07 | Roche Glycart Ag | Anticuerpos CEA |
DK2691417T3 (en) | 2011-03-29 | 2018-11-19 | Roche Glycart Ag | ANTIBODY FC VARIANTS |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
EP2710042A2 (en) * | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
UA115122C2 (uk) | 2011-05-21 | 2017-09-25 | Макродженікс, Інк. | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським |
EP2731970B1 (en) * | 2011-07-15 | 2018-11-28 | MorphoSys AG | Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt) |
WO2013012414A1 (en) | 2011-07-18 | 2013-01-24 | Medimmune, Llc | Dosing regimens for treatment of cea-expressing cancers |
CN103890008A (zh) * | 2011-08-17 | 2014-06-25 | 霍夫曼-拉罗奇有限公司 | 在顽固性肿瘤中抑制血管发生 |
LT2748201T (lt) * | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
JP6159724B2 (ja) | 2011-08-23 | 2017-07-05 | ロシュ グリクアート アーゲー | T細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法 |
TW201326212A (zh) | 2011-08-23 | 2013-07-01 | Roche Glycart Ag | 抗-mcsp抗體 |
RS57744B1 (sr) | 2011-08-23 | 2018-12-31 | Roche Glycart Ag | Bispecifični antigen vezujući molekuli |
US20130060011A1 (en) | 2011-08-23 | 2013-03-07 | Peter Bruenker | Fc-free antibodies comprising two fab fragments and methods of use |
CN103890006A (zh) | 2011-08-23 | 2014-06-25 | 罗切格利卡特公司 | 抗mcsp抗体 |
WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
EP2578230A1 (en) | 2011-10-04 | 2013-04-10 | Trion Pharma Gmbh | Removal of Tumor Cells from Intraoperative Autologous Blood Salvage |
US10851178B2 (en) * | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
PT2794905T (pt) | 2011-12-20 | 2020-06-30 | Medimmune Llc | Polipéptidos modificados para estrutura de anticorpos bispecíficos |
AU2013249985B2 (en) | 2012-04-20 | 2017-11-23 | Merus N.V. | Methods and means for the production of Ig-like molecules |
WO2014022540A1 (en) | 2012-08-02 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Multivalent antigen-binding proteins |
SG11201407580YA (en) | 2012-08-07 | 2014-12-30 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
AU2013302696B9 (en) | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
BR112015007120A2 (pt) | 2012-10-08 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
EP2953972B1 (en) | 2013-02-05 | 2020-07-08 | EngMab Sàrl | Method for the selection of antibodies against bcma |
JO3529B1 (ar) | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
EA201891502A1 (ru) * | 2013-02-26 | 2018-12-28 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
MX2015010350A (es) | 2013-02-26 | 2015-10-29 | Roche Glycart Ag | Moleculas de union a antigeno biespecificas que activan la celula t. |
CN104936985A (zh) * | 2013-02-26 | 2015-09-23 | 罗切格利卡特公司 | 双特异性t细胞活化性抗原结合分子 |
ES2790420T3 (es) | 2013-03-14 | 2020-10-27 | Scripps Research Inst | Conjugados de anticuerpos y de agentes de focalización usos de los mismos |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
WO2014141152A2 (en) | 2013-03-15 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Low concentration antibody formulations |
EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
SG11201509361TA (en) | 2013-05-28 | 2015-12-30 | Numab Ag | Novel antibodies |
EP3680254A1 (en) | 2013-12-17 | 2020-07-15 | F. Hoffmann-La Roche AG | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
PL3083689T3 (pl) | 2013-12-17 | 2020-10-19 | Genentech, Inc. | Przeciwciała anty-CD3 i sposoby ich zastosowania |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
KR102317315B1 (ko) * | 2014-08-04 | 2021-10-27 | 에프. 호프만-라 로슈 아게 | 이중특이적 t 세포 활성화 항원 결합 분자 |
WO2016019969A1 (en) | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
SG11201701157UA (en) | 2014-08-29 | 2017-03-30 | Hoffmann La Roche | Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1 |
WO2016036678A1 (en) | 2014-09-02 | 2016-03-10 | Medimmune, Llc | Formulations of bispecific antibodies |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
EP3204416A1 (en) | 2014-10-09 | 2017-08-16 | EngMab AG | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer |
US11952421B2 (en) | 2014-10-09 | 2024-04-09 | Bristol-Myers Squibb Company | Bispecific antibodies against CD3EPSILON and ROR1 |
RS61870B1 (sr) | 2014-11-14 | 2021-06-30 | Hoffmann La Roche | Antigen vezujući molekuli koji sadrže trimer liganda iz tnf familije |
MX2017006626A (es) | 2014-11-20 | 2017-08-21 | Hoffmann La Roche | Cadenas ligeras comunes y metodos de uso. |
EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
UA122676C2 (uk) | 2014-11-20 | 2020-12-28 | Ф. Хоффманн-Ля Рош Аг | Біспецифічна антигензв'язувальна молекула проти folr1 і cd3, що активує t-клітини |
EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
JP2018520642A (ja) | 2015-05-01 | 2018-08-02 | ジェネンテック, インコーポレイテッド | マスク抗cd3抗体及びその使用方法 |
FI3310814T3 (fi) | 2015-06-16 | 2023-09-21 | Hoffmann La Roche | HUMANISOITUJA JA AFFINITEETTIKYPSIÄ FcRH5-VASTA-AINEITA JA KÄYTTÖMENETELMIÄ |
KR20180042271A (ko) | 2015-08-03 | 2018-04-25 | 잉맵 에스에이알엘 | Bcma에 대응하는 단일클론 항체 |
WO2017055318A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Cd33xcd3 bispecific t cell activating antigen binding molecules |
KR20180073561A (ko) | 2015-10-02 | 2018-07-02 | 에프. 호프만-라 로슈 아게 | 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자 |
AR106365A1 (es) | 2015-10-02 | 2018-01-10 | Hoffmann La Roche | Moléculas biespecíficas de unión a antígeno activadoras de células t |
CN108026177B (zh) | 2015-10-02 | 2021-11-26 | 豪夫迈·罗氏有限公司 | 双特异性抗cd19xcd3 t细胞活化性抗原结合分子 |
US20170096495A1 (en) | 2015-10-02 | 2017-04-06 | Hoffmann-La Roche Inc. | Bispecific t cell activating antigen binding molecules |
CN108290954B (zh) | 2015-12-09 | 2022-07-26 | 豪夫迈·罗氏有限公司 | Ii型抗cd20抗体用于降低抗药物抗体形成 |
-
2014
- 2014-02-24 EA EA201891502A patent/EA201891502A1/ru unknown
- 2014-02-24 EA EA201500876A patent/EA031214B1/ru not_active IP Right Cessation
- 2014-02-24 BR BR112015015824-2A patent/BR112015015824B1/pt active IP Right Grant
- 2014-02-24 UA UAA201509085A patent/UA119320C2/uk unknown
- 2014-02-24 JP JP2015558476A patent/JP6133444B2/ja active Active
- 2014-02-24 NZ NZ708182A patent/NZ708182A/en unknown
- 2014-02-24 PE PE2015001762A patent/PE20151410A1/es active IP Right Grant
- 2014-02-24 PT PT147085070T patent/PT2961771T/pt unknown
- 2014-02-24 KR KR1020157022986A patent/KR101833602B1/ko active IP Right Grant
- 2014-02-24 KR KR1020187005120A patent/KR20180023035A/ko active Application Filing
- 2014-02-24 MY MYPI2015702806A patent/MY192312A/en unknown
- 2014-02-24 HU HUE14708507A patent/HUE047925T2/hu unknown
- 2014-02-24 MX MX2015008920A patent/MX2015008920A/es active IP Right Grant
- 2014-02-24 PL PL14708507T patent/PL2961771T3/pl unknown
- 2014-02-24 ES ES14708507T patent/ES2775207T3/es active Active
- 2014-02-24 US US14/188,486 patent/US10155815B2/en active Active
- 2014-02-24 EP EP19217855.6A patent/EP3708584A1/en active Pending
- 2014-02-24 KR KR1020217023163A patent/KR20210094673A/ko active Application Filing
- 2014-02-24 MA MA38308A patent/MA38308B1/fr unknown
- 2014-02-24 WO PCT/EP2014/053490 patent/WO2014131712A1/en active Application Filing
- 2014-02-24 KR KR1020207007753A patent/KR102282761B1/ko active Application Filing
- 2014-02-24 SI SI201431517T patent/SI2961771T1/sl unknown
- 2014-02-24 KR KR1020227043458A patent/KR20230004901A/ko not_active Application Discontinuation
- 2014-02-24 DK DK14708507.0T patent/DK2961771T3/da active
- 2014-02-24 RS RS20200230A patent/RS59992B1/sr unknown
- 2014-02-24 CN CN201910633487.XA patent/CN110437337A/zh active Pending
- 2014-02-24 SG SG11201504497TA patent/SG11201504497TA/en unknown
- 2014-02-24 AU AU2014222779A patent/AU2014222779B2/en active Active
- 2014-02-24 CN CN201480005567.6A patent/CN104936986B/zh active Active
- 2014-02-24 EP EP14708507.0A patent/EP2961771B1/en active Active
- 2014-02-24 LT LTEP14708507.0T patent/LT2961771T/lt unknown
- 2014-02-24 CA CA2891493A patent/CA2891493C/en active Active
- 2014-02-25 TW TW105104385A patent/TWI638832B/zh active
- 2014-02-25 TW TW103106320A patent/TWI534155B/zh active
- 2014-02-26 AR ARP140100602A patent/AR094896A1/es unknown
-
2015
- 2015-06-15 PH PH12015501340A patent/PH12015501340B1/en unknown
- 2015-07-09 MX MX2020009692A patent/MX2020009692A/es unknown
- 2015-07-14 CL CL2015001988A patent/CL2015001988A1/es unknown
- 2015-07-20 IL IL240045A patent/IL240045B/en active IP Right Grant
- 2015-07-28 CR CR20150393A patent/CR20150393A/es unknown
- 2015-12-08 HK HK15112068.5A patent/HK1211300A1/xx unknown
-
2017
- 2017-04-13 JP JP2017080029A patent/JP2017158565A/ja not_active Withdrawn
-
2018
- 2018-07-12 US US16/034,012 patent/US20180312589A1/en not_active Abandoned
- 2018-09-18 US US16/134,494 patent/US10781258B2/en active Active
- 2018-09-18 US US16/134,391 patent/US10781257B2/en active Active
- 2018-11-29 AU AU2018271329A patent/AU2018271329A1/en not_active Abandoned
-
2019
- 2019-02-22 US US16/282,708 patent/US20190177413A1/en not_active Abandoned
- 2019-11-05 JP JP2019200472A patent/JP6913145B2/ja active Active
- 2019-12-02 IL IL271102A patent/IL271102A/en unknown
-
2020
- 2020-02-24 HR HRP20200306TT patent/HRP20200306T1/hr unknown
- 2020-08-18 US US16/996,600 patent/US20200385470A1/en not_active Abandoned
- 2020-10-22 AU AU2020257119A patent/AU2020257119A1/en active Pending
- 2020-12-18 US US17/127,291 patent/US20210101979A1/en not_active Abandoned
-
2021
- 2021-05-03 US US17/306,068 patent/US20210253703A1/en not_active Abandoned
- 2021-05-03 US US17/306,079 patent/US20210253704A1/en not_active Abandoned
- 2021-05-07 JP JP2021079198A patent/JP2021129573A/ja active Pending
- 2021-11-12 US US17/525,101 patent/US20220064296A1/en not_active Abandoned
-
2022
- 2022-05-25 US US17/824,628 patent/US20230076791A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LT2961771T (lt) | Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams | |
HK1218425A1 (zh) | 雙特異性 細胞活化抗原結合分子 | |
HK1211299A1 (en) | Bispecific cell activating antigen binding molecules | |
IL268886A (en) | Dual-specific T cells that activate antigen-binding molecules | |
IL251292A0 (en) | Bispecific antigen binding molecules activate t cells against folr1 and cd3 | |
HK1254967A1 (zh) | 結合間皮素和cd3的雙特異性t細胞活化性抗原結合分子 | |
HUS2300033I1 (hu) | Bispecifikus, T-sejt-aktiváló antigénkötõ molekulák | |
HK1212709A1 (zh) | 針對 ε和 的雙特異性抗體 | |
HK1223629A1 (zh) | 結合分子 | |
HK1220919A1 (zh) | 抗體和雙特異性抗體及其用途 | |
HK1207094A1 (en) | Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine - t- | |
EP3019622A4 (en) | Bispecific cd3 and cd19 antigen binding contructs | |
HUE059815T2 (hu) | Bispecifikus SCFV immunofuziós (BIF) kötõdés a CD123-hoz és a CD3-hoz | |
EP2895203A4 (en) | ANTIGEN BINDING CONSTRUCTIONS FOR CD3 |